文献速递肝病消化道肿瘤与早癌

人类白细胞抗原变异与丙型肝炎病毒基因型修饰的肝细胞癌风险:一项全基因组关联研究

Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study.
PubMed 文献 · Hepatology · 2018-01-01

该研究对502例肝细胞癌病例和749例非肝细胞癌对照进行全基因组关联分析,并在1991-2013年社区队列的994例抗-HCV血清阳性者中评估HLA-DQB1变异的长期预测价值。结果显示HLA-DQB1*03:01与肝细胞癌风险降低相关(aHR 0.45),DQB1*06:02与风险升高相关(aHR 2.11),且HCV基因型修饰上述效应。

要点

  • HLA-DQB1*03:01与肝细胞癌风险降低独立相关,调整后HR为0.45(95%CI 0.30-0.68)。
  • HLA-DQB1*06:02与肝细胞癌风险升高独立相关,调整后HR为2.11(95%CI 1.34-3.34)。
  • HCV基因型修饰HLA-DQB1效应:DQB1*03:01的保护作用仅见于HCV基因1型,DQB1*06:02的风险仅见于非1型。

核心结论

  • HLA-DQB1与肝细胞癌独立相关,且HCV基因型修饰HLA-DQB1对肝细胞癌风险的影响。

研究设计与样本

  • 全基因组关联研究:使用Axiom-CHB全基因组芯片对502例肝细胞癌病例和749例非肝细胞癌对照进行基因分型。
  • 在1991-2013年期间社区队列收集的994例抗-HCV血清阳性者中进行HLA-DQB1基因分型,评估HLA变异对肝细胞癌风险的长期预测价值,采用Cox比例风险模型估计风险比和95%置信区间。

主要发现

  • 全基因组关联分析发现HLA-DQB1附近的8个单核苷酸多态性与肝细胞癌相关(P < 8.7 × 10-8)。
  • 长期随访显示HLA-DQB1*03:01和DQB1*06:02与肝细胞癌显著相关(P < 0.05),调整后风险比分别为0.45(95%CI 0.30-0.68)和2.11(95%CI 1.34-3.34)。
  • 按HCV基因型分层后,DQB1*03:01仅在HCV基因1型患者中显示保护效应,而DQB1*06:02仅在HCV非1型患者中增加肝细胞癌风险。
  • HLA插补分析显示与DQB1*06:02存在连锁不平衡的HLA-DRB1*15:01也增加肝细胞癌风险(比值比1.96,95%CI 1.31-2.93)。
  • 单倍型分析支持DQB1*03:01和DQB1*06:02分别为主要保护性和易感性变异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a genome-wide association study to discover genetic variants associated with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). We genotyped 502 HCC cases and 749 non-HCC controls using the Axiom-CHB genome-wide array. After identifying single-nucleotide polymorphism clusters located in the human leukocyte antigen (HLA) region which were potentially associated with HCC, HLA-DQB1 genotyping was performed to analyze 994 anti-HCV seropositives collected in the period 1991-2013 in a community-based cohort for evaluating long-term predictability of HLA variants for identifying the risk of HCC. Cox proportional hazards models were used to estimate the hazard ratios and 95% confidence intervals of HLA genotypes for determining the aforementioned HCC risk. Eight single-nucleotide polymorphisms in the proximity of HLA-DQB1 were associated with HCC (P < 8.7 × 10-8 ) in the genome-wide association study. Long-term follow-up showed a significant association with HLA-DQB1*03:01 and DQB1*06:02 (P < 0.05). The adjusted hazard ratios associated with HCC were 0.45 (0.30-0.68) and 2.11 (1.34-3.34) for DQB1*03:01 and DQB1*06:02, respectively. After stratification by HCV genotypes, DQB1*03:01 showed protective effects only in patients with HCV genotype 1, whereas DQB1*06:02 conferred risk of HCC only in patients with HCV non-1 genotypes. HLA imputation analyses revealed that HLA-DRB1*15:01, which is in linkage disequilibrium with DQB1*06:02, also increased the risk of HCC (odds ratio, 1.96; 95% confidence interval, 1.31-2.93). Haplotype analysis supported that DQB1*03:01 and DQB1*06:02 are primarily protective and susceptible variants, respectively. Conclusion: HLA-DQB1 was independently associated with HCC; HCV genotypes modified the effects of HLA-DQB1 on the risk of HCC. (Hepatology 2018;67:651-661).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lee MH, Huang YH, Chen HY, et al. Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study. Hepatology. 2018. PMID: 28921602. doi:10.1002/hep.29531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。